Personal Genome Diagnostics names first CEO

After six years of existence and raising more than $20 million, Personal Genome Diagnostics has its first full-time CEO.
Douglas Ward will head the Canton-based Johns Hopkins spinout and sit on its board, the company announced Monday.
Ward has worked in medical diagnostics for 25 years, most recently serving as Vice President of Companion Diagnostics at Ventana Medical Systems. He has also worked at GE Healthcare and Bayer Healthcare.
Founded in 2010 by Hopkins cancer researchers Victor Velculescu and Luis Diaz, Personal Genome Diagnostics specializes in technology to assist cancer genome testing. The company closed a $21.4 million Series A led be NEA in 2015.
Personal Genome Diagnostics previously did not have a CEO. A spokeswoman said Ward is “expected to build on the company’s record of strong growth and provide experienced leadership for the further development of key product lines.”